While COVID 2.0 related headwinds are likely to delay the recovery process, we remain confident in the resilience of the business model. We maintain a BUY on the stock. We value UJSFB at 1.8x FY23E ABV and arrive at a target price of Rs. 37/share, implying an upside of 21% from CMP.